ReviewDrugs2020
Advances in Long-Acting Agents for the Treatment of HIV Infection.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The safety of cabotegravir in pregnancy: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- The Acceptability of a Real-Time Medication Monitoring-Based Digital Adherence Tool Among Young People Living with HIV in Malawi.AIDS and behavior · 2026Trial
- Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.BMC infectious diseases · 2022Trial
- Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.Journal of the International Association of Providers of AIDS CareTrial
- Scalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program.Open forum infectious diseases · 2026Article
- Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.Clinical and translational science · 2026Article
- Safety and Virological Outcomes of a Modified Albuvirtide Intensification Regimen with Standard ART in People with HIV.Infection and drug resistance · 2026Article
- Using a paper-based checklist for promoting increased access to long-acting injectable cabotegravir/rilpivirine among people living with HIV in Toronto: Lessons learned from a quality improvement initiative.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025Article
- Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports.Retrovirology · 2025Article
- Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.BMC infectious diseases · 2024Article
- Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments.BMC infectious diseases · 2024Article
- A case of multiple ART intolerance responds to Albuvirtide and Dolutegravir: Case report and literature review.Heliyon · 2024Article
- HIV/AIDS in Indonesia: current treatment landscape, future therapeutic horizons, and herbal approaches.Frontiers in public health · 2024Review
- Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response.Scientific reports · 2023Article
- Article
- The risk of drug resistance during long-acting antimicrobial therapy.Proceedings. Biological sciences · 2022Article
- Microfluidic Devices for HIV Diagnosis and Monitoring at Point-of-Care (POC) Settings.Biosensors · 2022Review
- Effect of Social Determinants of Health on Uncontrolled Human Immunodeficiency Virus (HIV) Infection Among Persons With HIV in San Francisco, California.Open forum infectious diseases · 2022Article
- Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing.Human vaccines & immunotherapeutics · 2022Review
- Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.AIDS and behavior · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Long-acting antiretroviral therapy holds the promise of new options for human immunodeficiency virus (HIV) treatment beyond the current paradigm of daily oral pills. Of particular interest is their potential role in addressing challenges with adherence to oral therapy and treatment fatigue. Similar to other conditions where long-acting formulations have proven effective such as contraception and mental health, long-acting antiretroviral therapy could provide additional treatment choices to people with HIV. This review provides an outline of the current landscape of long-acting antiretroviral therapy for HIV treatment, both approved and under development, including cabotegravir, rilpivirine, leronlimab, islatravir, albuvirtide, GS-6207, and broadly neutralizaing antibodies. However, there are a number of research gaps for long-acting antiretroviral therapy including issues regarding resistance and understudied populations, and this review highlights some of the challenges that will need to be addressed for clinical implementation of these novel treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.